disulfiram and amg531

disulfiram has been researched along with amg531 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW	1

Other Studies

2 other study(ies) available for disulfiram and amg531

Article	Year
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Perspectives on SARS-CoV-2 Main Protease Inhibitors. Journal of medicinal chemistry, 2021, 12-09, Volume: 64, Issue:23 Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors	2021

Article

Year

FDA-approved drug labeling for the study of drug-induced liver injury.

Drug discovery today, 2011, Volume: 16, Issue:15-16

Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011

Perspectives on SARS-CoV-2 Main Protease Inhibitors.

Journal of medicinal chemistry, 2021, 12-09, Volume: 64, Issue:23

Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors

2021